Brady Huggett

Serono, IVAX Sign To Develop Cladribine As Oral MS Treatment

Oct. 31, 2002

By Brady Huggett

Serono, IVAX Sign To Develop Cladribine As Oral MS Treatment

Oct. 31, 2002

By Brady Huggett

Exelixis, GSK Enter Deal With $134M Guarantee, Huge Potential

Oct. 30, 2002

By Brady Huggett

When Exelixis Inc. was younger, it described itself as a model systems genetics and comparative genomics company. But a deal rich with up-front and potential funding disclosed after the markets closed Monday showed it has successfully made the move into drugs. (BioWorld Today)

Exelixis, GSK Enter Deal With $134M Guarantee, Huge Potential

Oct. 30, 2002

By Brady Huggett

When Exelixis Inc. was younger, it described itself as a model systems genetics and comparative genomics company. But a deal rich with up-front and potential funding disclosed after the markets closed Monday showed it has successfully made the move into drugs. (BioWorld Today)